Skye Bioscience, Inc. Common Stock

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE